Matching articles for "Stribild"
Biktarvy - Another INSTI-Based Combination for HIV
The Medical Letter on Drugs and Therapeutics • August 13, 2018; (Issue 1553)
The FDA has approved Biktarvy (Gilead), a once-daily,
fixed-dose combination of bictegravir, a new integrase
strand transfer inhibitor (INSTI), and the nucleoside
reverse transcriptase inhibitors (NRTIs)...
The FDA has approved Biktarvy (Gilead), a once-daily,
fixed-dose combination of bictegravir, a new integrase
strand transfer inhibitor (INSTI), and the nucleoside
reverse transcriptase inhibitors (NRTIs) emtricitabine
and tenofovir alafenamide (TAF), for treatment of HIV-1
infection in adults. The new combination is indicated for
use in patients who are antiretroviral-naive or who have
been virologically suppressed on a stable antiretroviral
regimen for ≥3 months with no history of treatment
failure and no known substitutions associated with
resistance to any component of the combination.
Genvoya - A New 4-Drug Combination for HIV
The Medical Letter on Drugs and Therapeutics • February 15, 2016; (Issue 1488)
The FDA has approved Genvoya (Gilead), a fixed-dose
combination of the integrase strand transfer
inhibitor (INSTI) elvitegravir, the pharmacokinetic
enhancer cobicistat, and the...
The FDA has approved Genvoya (Gilead), a fixed-dose
combination of the integrase strand transfer
inhibitor (INSTI) elvitegravir, the pharmacokinetic
enhancer cobicistat, and the nucleoside/nucleotide
reverse transcriptase inhibitors (NRTIs) emtricitabine
and tenofovir alafenamide, for treatment of HIV-1 infection in patients ≥12 years old. This is the first
approval for tenofovir alafenamide (TAF), a tenofovir
prodrug. Stribild, a fixed-dose combination of
elvitegravir, cobicistat, emtricitabine, and tenofovir
disoproxil fumarate (TDF), was approved in 2012.
Elvitegravir (Vitekta) for HIV
The Medical Letter on Drugs and Therapeutics • January 18, 2016; (Issue 1486)
The FDA has approved elvitegravir (Vitekta – Gilead),
an integrase strand transfer inhibitor (INSTI), for use
with a protease inhibitor (PI) plus ritonavir and other
antiretroviral drugs for treatment of...
The FDA has approved elvitegravir (Vitekta – Gilead),
an integrase strand transfer inhibitor (INSTI), for use
with a protease inhibitor (PI) plus ritonavir and other
antiretroviral drugs for treatment of HIV-1 infection
in treatment-experienced adults. Elvitegravir is also
available in a fixed-dose combination (Stribild) with
the pharmacokinetic enhancer cobicistat and the
nucleoside/nucleotide reverse transcriptase inhibitors
(NRTIs) emtricitabine and tenofovir disoproxil
fumarate (DF). A similar combination (Genvoya) that
includes tenofovir alafenamide instead of tenofovir DF
was recently approved by the FDA and will be reviewed
in a future issue.
Cobicistat (Tybost) and Combinations for HIV
The Medical Letter on Drugs and Therapeutics • November 23, 2015; (Issue 1482)
Cobicistat, a pharmacokinetic enhancer that boosts
levels of some HIV drugs but has no antiretroviral
activity of its own, is now available alone as Tybost
(Gilead) and in fixed-dose combinations with...
Cobicistat, a pharmacokinetic enhancer that boosts
levels of some HIV drugs but has no antiretroviral
activity of its own, is now available alone as Tybost
(Gilead) and in fixed-dose combinations with the
protease inhibitors atazanavir (Evotaz — BMS) and
darunavir (Prezcobix — Janssen) for treatment of
HIV-1 infection. Both atazanavir and darunavir have
traditionally been used in combination with the
CYP3A inhibitor ritonavir (Norvir) to boost their serum
concentrations, but neither is available in a fixed-dose
combination with ritonavir.
Triumeq: A 3-Drug Combination for HIV
The Medical Letter on Drugs and Therapeutics • January 5, 2015; (Issue 1459)
The FDA has approved Triumeq (Viiv Healthcare),
a fixed-dose combination of the integrase strand
transfer inhibitor (INSTI) dolutegravir and the
nucleoside reverse transcriptase inhibitors (NRTIs)
abacavir...
The FDA has approved Triumeq (Viiv Healthcare),
a fixed-dose combination of the integrase strand
transfer inhibitor (INSTI) dolutegravir and the
nucleoside reverse transcriptase inhibitors (NRTIs)
abacavir and lamivudine, for once-daily treatment of
HIV-1 infection. Dolutegravir (Tivicay) was approved
as a single agent in 2013.
Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • February 1, 2014; (Issue 138)
Antiretroviral therapy is recommended for all HIV-infected
patients, both to reduce the risk of disease
progression and to prevent transmission of the virus to
others. Various guidelines for treatment of HIV...
Antiretroviral therapy is recommended for all HIV-infected
patients, both to reduce the risk of disease
progression and to prevent transmission of the virus to
others. Various guidelines for treatment of HIV infection
are available.
Dolutegravir (Tivicay) for HIV
The Medical Letter on Drugs and Therapeutics • September 30, 2013; (Issue 1426)
The FDA has approved dolutegravir (doll-you-TEG-rah-veer;
Tivicay – Viiv Healthcare), an integrase strand
transfer inhibitor (INSTI), for treatment of HIV-1 infection
in adults and in children ≥12 years...
The FDA has approved dolutegravir (doll-you-TEG-rah-veer;
Tivicay – Viiv Healthcare), an integrase strand
transfer inhibitor (INSTI), for treatment of HIV-1 infection
in adults and in children ≥12 years old who weigh at least 40 kg. It is the third INSTI to be approved by the FDA; raltegravir
and elvitegravir were approved earlier.
A 4-Drug Combination (Stribild) for HIV
The Medical Letter on Drugs and Therapeutics • November 26, 2012; (Issue 1404)
The FDA has approved a fixed-dose combination of
the integrase strand transfer inhibitor (INSTI) elvitegravir,
the pharmacokinetic enhancer cobicistat, and
the nucleoside/nucleotide reverse transcriptase...
The FDA has approved a fixed-dose combination of
the integrase strand transfer inhibitor (INSTI) elvitegravir,
the pharmacokinetic enhancer cobicistat, and
the nucleoside/nucleotide reverse transcriptase inhibitors
(NRTIs) emtricitabine and tenofovir disoproxil
fumarate (Stribild – Gilead) for treatment of HIV-1
infection in antiretroviral treament-naïve adults.
Elvitegravir is the second INSTI to be approved by the
FDA for use in HIV treatment; raltegravir (Isentress)
was the first.